Access the Akari CEO Corner here TAMPA, FL and LONDON – January 9, 2026 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Press Release
Akari Therapeutics to Present at the 2026 Biotech Showcase
In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari’s ADC platform, …
[Read more...] about Akari Therapeutics to Present at the 2026 Biotech Showcase
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug …
[Read more...] about Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Will Exclusively Partner with Industry Leader WuXi XDC For This Key IND-enabling Work Tampa, FL and London – December 23, 2025 – Akari …
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Access the Akari CEO Corner here BOSTON and LONDON – November 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing …
[Read more...] about Akari Therapeutics Announces Release of the Next CEO Corner Segment
